Study finds headache drug could prevent overuse of acute migraine medications
Chronic migraine is a neurological condition estimated to affect up to 2.2% of people globally
Read More
Tag: atogepant
AbbVie reveals results from pivotal atogepant trial
Study has been focusing on atogepant for the prevention of episodic migraine attacks
Read More
Allergan’s experimental migraine drug hits trial targets
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
